Blair William & CO Uni Qure N.V. Transaction History

Blair William & CO

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$11.12 - $22.2 $2,012 - $4,018	-181 Reduced 0.74%	24,209 $277,000
Q1 2023 May 12, 2023	SELL	$18.7 - $23.07 $90,489 - $111,635	-4,839 Reduced 16.56%	24,390 $491,000
Q4 2022 Feb 10, 2023	BUY	$18.12 - $27.32 $529,629 - $798,536	29,229 New	29,229 $662,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.